Americas Gastrointestinal Drugs Market Research Report, by Drug Category (Acid Neutralizers, Laxatives and Antidiarrheal, Anti-inflammatory drugs, and Others), By Route of Administration (Oral, Parenteral, Rectal), By disease type (Gastroesophageal Reflux Disease, Inflammatory Bowel Disease and Other), By end user (Hospital Pharmacies, Retail Pharmacies and Other) - Forecast till 2032

TABLE OF CONTENTS

1 INTRODUCTION

1.1 DEFINITION

1.2 SCOPE OF STUDY

1.2.1 RESEARCH OBJECTIVE

1.2.2 ASSUMPTIONS & LIMITATIONS

1.2.2.1 ASSUMPTIONS

1.2.2.2 LIMITATIONS

1.3 MARKET STRUCTURE:

2 RESEARCH METHODOLOGY

2.1 RESEARCH PROCESS:

2.2 PRIMARY RESEARCH

2.3 SECONDARY RESEARCH:

3 MARKET DYNAMICS

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 MACROECONOMIC INDICATORS

4 MARKET FACTOR ANALYSIS

4.1 PORTERS FIVE FORCES MODEL

4.2 BARGAINING POWER OF SUPPLIERS

4.3 BARGAINING POWER OF BUYERS

4.4 THREAT OF NEW ENTRANTS

4.5 THREAT OF SUBSTITUTES

4.6 INTENSITY OF RIVALRY

5. AMERICAS GASTROINTESTINAL DRUG MARKET, BY DRUG CATEGORY

5.1 ACID NEUTRALIZERS

5.1.1 ANTACID

5.1.2 H2 ANATAGONISTS

5.1.3 PROTON PUMP INHIBITORS

5.1.4 OTHERS

5.2 LAXATIVES & ANTIDIARRHEAL

5.3 ANTINFLAMMATORY

5.4 ANTIEMETIC

5.5 OTHER

6. AMERICAS GASTROINTESTINAL DRUG MARKET, BY ROUTE OF ADMINISTRATION

6.1 ORAL

6.2 PARENTAL

6.3 RECTAL

7. AMERICAS GASTROINTESTINAL DRUG MARKET, BY DISEASES TYPE

7.1 GASTROESPHAGEAL REFLUX DISEASES

7.2 INFLAMMATORY BOWEL DISEASES

7.2.1 CHRON’S DISEASE

7.2.2 ULCERTAVIE COLITIS

7.2.2.1 ULCERATIVE PROCTITIS

7.2.2.2 PROCTOSIGMOIDITIS

7.2.2.3 LEFT SIDED COLITIS

7.2.2.4 PANCOLITIS

7.2.2.5 ACUTE SEVERE ULCERTATIVE COLITIS

7.3 OTHER.

8. AMERICAS GASTROINTESTINAL DRUG MARKET, BY END USERS

8.1 HOSPITAL PHARMACIES

8.2 RETAIL PHARMACIES

8.3 OTHERS

9. AMERICAS GASTROINTESTINAL DRUG MARKET, BY REGION

9.1 INTRODUCTION

9.1.2 NORTH AMERICA

91.3. SOUTH AMERICA

10. COMPETITIVE LANDSCAPE

10.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS

10.1.1 STRATEGIC PARTNERSHIP

10.1.2 MERGER & ACQUISITION

11 COMPANY PROFILE

11.1 ABBVIE INC.

11.1.1 OVERVIEW

11.1.2 PRODUCT OVERVIEW

11.1.3 FINANCIALS

11.1.4 KEY DEVELOPMENTS

11.2 ABBOTT LABORATORIES

11.2.1 OVERVIEW

11.2.2 PRODUCT OVERVIEW

11.2.3 FINANCIALS

11.2.4 KEY DEVELOPMENTS

11.3 ALLERGEN PLC.

11.3.1 OVERVIEW

11.3.2 PRODUCT OVERVIEW

11.3.3 FINANCIALS

11.3.4 STRATEGY

11.3.5 KEY DEVELOPMENT

11.4 BAYER AG

11.4.1 OVERVIEW

11.4.2 PRODUCT OVERVIEW

11.4.3 FINANCIALS

11.4.4 KEY DEVELOPMENTS

11.5 BOEHRINGER INGELHEIM GMBH

11.5.1 OVERVIEW

11.5.2 PRODUCT OVERVIEW

11.5.3 FINANCIALS

11.5.4 KEY DEVELOPMENTS

11.6 GALXOSMITHKLINE

11.6.1 OVERVIEW

11.6.2 PRODUCT OVERVIEW

11.6.3 FINANCIALS

11.6.4 KEY DEVELOPMENTS

11.7 JASSEN PHARMACEUTICALS INC

11.7.1 OVERVIEW

11.7.2 PRODUCT OVERVIEW

11.7.3 FINANCIALS

11.7.4 KEY DEVELOPMENTS

11. 8 OTHERS